Open AccessA Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
Author(s) -
Romuald Girard,
Yan Li,
Agnieszka Stadnik,
Robert Shenkar,
Nicholas Hobson,
Sharbel Romanos,
Abhinav Srinath,
Thomas Moore,
Rhonda Lightle,
Abdallah Shkoukani,
Amy Akers,
Timothy J. Carroll,
Gregory A. Christoforidis,
James I. Koenig,
Cornelia Lee,
Kristina Piedad,
Steven M. Greenberg,
Helen Kim,
Kelly D. Flemming,
Yuan Ji,
Issam A. Awad
Publication year - 2021
Publication title -
neurosurgery/neurosurgery online
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.455
H-Index - 198
eISSN - 1081-1281
pISSN - 0148-396X
DOI - 10.1093/neuros/nyaa478
Subject(s) - medicine , biomarker , bleed , context (archaeology) , bioinformatics , intensive care medicine , pathology , radiology , surgery , paleontology , biochemistry , chemistry , biology
Cerebral cavernous angioma (CA) is a capillary microangiopathy predisposing more than a million Americans to premature risk of brain hemorrhage. CA with recent symptomatic hemorrhage (SH), most likely to re-bleed with serious clinical sequelae, is the primary focus of therapeutic development. Signaling aberrations in CA include proliferative dysangiogenesis, blood-brain barrier hyperpermeability, inflammatory/immune processes, and anticoagulant vascular domain. Plasma levels of molecules reflecting these mechanisms and measures of vascular permeability and iron deposition on magnetic resonance imaging are biomarkers that have been correlated with CA hemorrhage.